Quebec, Canada-based AEterna says that it has completed the integrationof its subsidiaries AEterna GmbH and Zentaris. The company acquired the latter unit from Germany's Degussa for $52 million during December 2002 (Marketletter January 6) and the successful completion of the merger has triggered the settling of the $40 million outstanding balance with Degussa. Separately, AEterna has entered into a $25 million loan agreement which will be used to support current operating activities at the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze